Azenta (AZTA) Q4 2025: MultiOmics Hits Record $73M, Margin Expansion Signals Operational Reset
Azenta’s operational overhaul delivered record MultiOmics revenue and over 300 basis points of margin expansion, even as macro headwinds weighed on capital equipment demand. The company’s decentralized structure and Azenta Business System are embedding accountability and speed, while management eyes mid-single-digit growth in Sample Management Solutions and continued price optimization. Investors should watch for a back-half acceleration as commercial investments and pricing initiatives ramp, with further detail expected at the upcoming Investor Day.
Summary
- MultiOmics Record Quarter: Segment strength offset macro softness, validating portfolio resilience and commercial execution.
- Margin Expansion Momentum: Operational discipline and cost actions yielded over 300 basis points of margin improvement.
- Back-Half Growth Inflection: Commercial reinvestment and price optimization position Azenta for an accelerated second half in 2026.
Performance Analysis
Azenta closed fiscal 2025 with 4% organic revenue growth and 310 basis points of adjusted EBITDA margin expansion, underscoring the impact of its operational transformation. The MultiOmics segment delivered a record $73 million in revenue, growing 11% reported and 10% organically. Next-generation sequencing, or NGS, led the charge with a 50% YoY volume increase, while gene synthesis stabilized and outperformed in China. Sample Management Solutions (SMS) contributed $86 million, with consumables and instruments providing stability even as cryogenic stores faced delayed customer CapEx.
Gross margin for the quarter was 46.7%, down modestly due to product mix in MultiOmics, but offset by improved execution in SMS. Free cash flow improved markedly YoY, driven by working capital gains. The balance sheet remains robust, with $546 million in cash and no debt, providing ample flexibility for growth investments and tuck-in M&A. Notably, management expects SMS to deliver mid-single-digit growth in 2026, supported by a deep backlog and new commercial leadership.
- MultiOmics Outperformance: Record revenue, strong NGS volumes, and China strength balanced Sanger sequencing decline.
- SMS Margin Resilience: Product mix and cost control drove a 180 basis point margin improvement in SMS.
- Cash Flow Rebound: Free cash flow up $26 million YoY, reflecting operational discipline and working capital management.
While macro uncertainty and government shutdowns dampened Q1 2026 visibility, Azenta’s core businesses demonstrated resilience, setting up for a stronger second half as investments in commercial and pricing initiatives take hold.
Executive Commentary
"We've created a simpler, more accountable organization through the implementation of the Azenta Business System, ABS, which is the framework for how we operate. It brings together lean principles, daily management routines, and structured problem-solving... Operational excellence is no longer just a goal. It's embedded in how our teams work every day."
John Marotta, President and Chief Executive Officer
"I'm pleased to report an adjusted EBITDA margin of 13% in the fourth quarter and 11.2% for the full year, representing expansion of approximately 230 basis points in Q4 and 310 basis points for the full year. These results reflect the continued benefits of our operational turnaround and disciplined cost execution delivered in the face of a challenging macro environment."
Lawrence Lin, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Decentralized Operating Model
Azenta moved from a centralized to a decentralized structure, empowering operating companies and product managers with direct accountability and regional go-to-market models. This shift enables faster decisions, closer customer alignment, and improved responsiveness, with new general managers and commercial leaders now embedded across all business lines.
2. Azenta Business System (ABS) Implementation
ABS, the company’s process excellence framework, integrates lean, daily management, and problem-solving into core operations. Kaizens across manufacturing and commercial teams delivered measurable gains in quality, on-time delivery, and productivity, with cultural adoption now driving bottom-up improvements.
3. Commercial Reinvestment and Price Optimization
Azenta reinvested in commercial infrastructure, adding nearly 20 new sales heads and upgrading leadership, particularly in SMS and SRS (Sample Repository Solutions, long-term sample storage contracts). The company is now leveraging contractually-embedded price escalators and streamlined systems to drive incremental revenue, a lever previously underutilized.
4. Balanced Capital Allocation and M&A Focus
With $546 million in cash and no debt, Azenta is prioritizing capital deployment across organic growth, tuck-in M&A in SRS, CNI (Consumables & Instruments), and synthesis, as well as share repurchases. Management signaled 2026 as a year for executing targeted acquisitions, with a reset foundation now in place to absorb new assets.
5. Portfolio Resilience and Market Positioning
Azenta’s portfolio spans critical sample management, automation, and multiomics workflows that address customer needs for consolidation, outsourcing, and automation. The company’s outgrowth versus the 1%–2% market reflects share gains, especially as pharma and biopharma customers seek trusted partners amid industry volatility.
Key Considerations
Azenta’s operational reset is yielding tangible results, but the full impact of commercial investments and pricing actions will be realized over the course of 2026. The company’s ability to maintain outgrowth, expand margins, and deploy capital with discipline are central to its investment case.
Key Considerations:
- Commercial Engine Ramping: Newly hired sales teams and leaders are expected to drive SMS and SRS growth, with a pronounced impact in the second half of 2026.
- Price Optimization Initiatives: Contractual price escalators in SRS and CNI are now being systematically executed, providing a new revenue lever.
- Macro and Government Funding Risks: Delayed CapEx and government shutdowns have pushed bookings into future quarters, particularly in the U.S. and academic markets.
- MultiOmics Normalization: NGS growth is expected to moderate to mid-single digits as volumes and pricing stabilize post-2025 surge.
- M&A Pipeline Readiness: The company is poised for tuck-in acquisitions, especially in SRS and automation, with a stable foundation to integrate new assets.
Risks
Macro headwinds remain a central risk, with capital spending delays and government funding uncertainty impacting near-term visibility. While Azenta’s portfolio is resilient, further deterioration in biopharma or academic funding, or a prolonged CapEx freeze, could challenge growth targets. Execution risk around integrating new M&A and realizing price optimization benefits should also be monitored.
Forward Outlook
For Q1 2026, Azenta guided to:
- Revenue decline of 1%–2% YoY, reflecting macro and government funding headwinds
For full-year 2026, management guided:
- Organic revenue growth of 3%–5%
- Adjusted EBITDA margin expansion of approximately 300 basis points
- Free cash flow improvement of over 30% YoY
Management expects a slower first half, with acceleration in the back half as commercial and pricing initiatives gain traction. Investor Day in December will detail the multi-year growth strategy and capital allocation priorities.
Takeaways
Azenta’s decentralized model and operational discipline are driving measurable gains, but the path to sustained outperformance hinges on commercial execution and macro recovery.
- Commercial and Price Levers in Focus: The next phase of growth depends on the ramp of new sales teams and systematic price optimization, especially in SMS and SRS.
- Margin Expansion as a Core Theme: Over 300 basis points of margin improvement demonstrates operational reset, but further gains are expected as ABS deepens across the company.
- Second-Half Acceleration Key: Investors should watch for evidence of revenue and margin inflection as delayed bookings and new initiatives convert to growth in the back half of 2026.
Conclusion
Azenta exits 2025 as a leaner, more accountable, and operationally disciplined organization, with record MultiOmics performance and significant margin expansion. The company’s decentralized structure and commercial reinvestment position it for back-half growth acceleration, but macro and execution risks remain. Investor Day will be pivotal in clarifying the long-term growth and capital deployment narrative.
Industry Read-Through
Azenta’s quarter offers a clear read-through for the life sciences tools and automation sector: portfolio breadth, operational agility, and regional go-to-market models are critical to navigating macro and funding volatility. The normalization of NGS growth and persistent CapEx delays suggest broader industry moderation, while the focus on price optimization and attachment rates signals a shift toward extracting more value from installed bases. Companies with deep customer touchpoints and resilient recurring revenue streams will be best positioned to weather ongoing uncertainty and capitalize on industry consolidation trends.